Related Experiment Video

Updated: Apr 30, 2026

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

8.7K

Dystrophin as a therapeutic biomarker: are we ignoring data from the past?

Steve D Wilton1, Sue Fletcher1, Kevin M Flanigan2

  • 1Western Australian Neuroscience Research Institute and Centre for Comparative Genomics, Murdoch University, Murdoch, Western Australia, Australia.

Neuromuscular Disorders : NMD
|April 29, 2014
PubMed
Abstract

No abstract available in PubMed .

Keywords:
BiomarkerDuchenne muscular dystrophyDystrophinExon skipping

More Related Videos

Assessing Functional Performance in the Mdx Mouse Model10:32

Assessing Functional Performance in the Mdx Mouse Model

Published on: March 27, 2014

32.7K
Immunolabelling Myofiber Degeneration in Muscle Biopsies06:37

Immunolabelling Myofiber Degeneration in Muscle Biopsies

Published on: December 5, 2019

8.5K

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
1.7K